BioSpace News Archive

AACC—in collaboration with the American Diabetes Association —released evidence-based guidelines to help diagnose and manage patients with diabetes using the latest laboratory-analysis tools.

ADC Therapeutics SA (NYSE: ADCT) today announced that it plans to discontinue the Phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three new employees to purchase an aggregate of 20,000 ordinary shares under Avadel’s 2021 Inducement Plan.

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced a series of leadership changes and appointments, designed to ensure a seamless transition into the next stage of growth for the company.

Ardelyx, Inc. (Nasdaq: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present on behalf of the company at the virtual H.C. Wainwright 2nd Annual Kidney Conference on Tuesday, July 25, 2023 at 2:00 P.M. Eastern Time.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that it will report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10, 2023.

Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI) announced that Robert (“Chip”) Hance has stepped down from the Company’s Board of Directors (the “Board”) effective July 19, 2023, and that Dr. John DeFord has been appointed to the Board effective July 20, 2023.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2023 after market close on Thursday, August 3, 2023.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2023 on Thursday, July 27, 2023, after the market closes.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 3, 2023, following the release of its second quarter 2023 financial results.